Amplia Therapeutics Ltd
ASX:ATX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Signatureglobal (India) Ltd
NSE:SIGNATURE
|
IN |
Amplia Therapeutics Ltd
Common Stock
Amplia Therapeutics Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amplia Therapeutics Ltd
ASX:ATX
|
Common Stock
AU$193.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Common Stock
$1.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
CSL Ltd
ASX:CSL
|
Common Stock
$206m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Race Oncology Ltd
ASX:RAC
|
Common Stock
AU$81.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Common Stock
AU$480m
|
CAGR 3-Years
9%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Common Stock
AU$369.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
24%
|
CAGR 10-Years
23%
|
|
Amplia Therapeutics Ltd
Glance View
Amplia Therapeutics Ltd. is a medical biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-12-23. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).
See Also
What is Amplia Therapeutics Ltd's Common Stock?
Common Stock
193.4m
AUD
Based on the financial report for Sep 30, 2025, Amplia Therapeutics Ltd's Common Stock amounts to 193.4m AUD.
What is Amplia Therapeutics Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
7%
Over the last year, the Common Stock growth was 24%. The average annual Common Stock growth rates for Amplia Therapeutics Ltd have been 8% over the past three years , 7% over the past five years .
